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CD36 mediates the transfer of fatty acids (FAs) across the plasma membranes of muscle and adipose cells, 
thus playing an important role in regulating peripheral FA metabolism in vivo. In the proximal intestine, 
CD36 is localized in abundant quantities on the apical surface of epithelial cells, a pattern similar to that of 
other proteins implicated in the uptake of dietary FAs. To define the role of CD36 in the intestine, we exam-
ined FA utilization and lipoprotein secretion by WT and CD36-null mice in response to acute and chronic 
fat feeding. CD36-null mice given a fat bolus by gavage or fed a high-fat diet accumulated neutral lipid in the 
proximal intestine, which indicated abnormal lipid processing. Using a model in which mice were equipped 
with lymph fistulae, we obtained evidence of defective lipoprotein secretion by directly measuring lipid 
output. The secretion defect appeared to reflect an impaired ability of CD36-null enterocytes to efficient-
ly synthesize triacylglycerols from dietary FAs in the endoplasmic reticulum. In the plasma of intact mice, 
the reduced intestinal lipid secretion was masked by slow clearance of intestine-derived lipoproteins. The 
impaired clearance occurred despite normal lipoprotein lipase activity and likely reflected feedback inhibi-
tion of the lipase by FAs due to their defective removal from the plasma. We conclude that CD36 is important 
for both secretion and clearance of intestinal lipoproteins. CD36 deficiency results in hypertriglyceridemia 
both in the postprandial and fasting states and in humans may constitute a risk factor for diet-induced type 
2 diabetes and cardiovascular disease.
Introduction
CD36 is a multiligand scavenger receptor expressed on the plas-
ma membrane by many cells such as platelets, monocytes, and 
adipocytes, as well as epithelial cells of the retina, mammary gland, 
and small intestine (reviewed in ref. 1). CD36 appears to be involved 
in many cellular functions such as cell adhesion (2), angiogenesis 
(3), and lipoprotein binding/endocytosis (4). The protein is also 
known as fatty acid (FA) translocase, or FAT, since it is implicated 
in facilitating uptake of long-chain FAs (5).
Genetic ablation of the Cd36 gene in mice results in impaired 
FA uptake by numerous tissues (5). Fasting plasma triacylglycerol 
(TAG) levels are also increased (6) and redistributed from LDL to 
VLDL. On the other hand, muscle-targeted CD36 overexpression 
reduces plasma FA and VLDL-associated TAG levels (7). In the 
spontaneously hypertensive rat, mutations in the Cd36 gene were 
identified and linked to the hypertriglyceridemia, high FA levels, 
and insulin resistance that are characteristic of this model (8–10), 
and these symptoms are improved by expression of the WT protein. 
In summary, the findings from studies on rodents document a role 
for CD36 in the metabolism of FAs and TAGs.
In humans, CD36 deficiency was first identified in patients 
with refractoriness to multiple platelet transfusions (11) and 
is relatively common (2–7%) in persons of Asian and African 
descent (12, 13). CD36-deficient subjects may present with high 
blood pressure and insulin resistance (14) as well as plasma lipid 
abnormalities. With fasting, high plasma TAG and reduced 
HDL-associated cholesterol levels were reported by Miyaoka et 
al. (14), while Yanai et al. observed elevated levels of LDL-associ-
ated cholesterol (12). In white people, common polymorphisms 
in the CD36 gene are associated with elevated blood FA levels 
(15). Kuwasako et al. further reported increased plasma levels of 
TAGs and apoB-48 in the postprandial state (16). Thus, CD36 
deficiency or mutations in the CD36 gene are associated with 
abnormal plasma lipid levels in humans.
The role of CD36 in modulating the uptake and utilization 
of intestine-derived lipids is currently unknown. In humans 
and mice, CD36 is detected in epithelial cells of the small intes-
tine along the gastrocolic and crypt-to-villus axes in a pattern 
paralleling that of other proteins implicated in FA uptake, 
such as intestinal and liver FA-binding proteins (17–19). 
Immunofluorescence studies revealed a polarized distribution 
of CD36 along the apical, brush border membranes, the primary 
site of intestinal FA uptake (19). To directly examine whether 
CD36 facilitates the utilization of dietary FAs, we measured FA 
uptake and processing by intestines of WT and CD36-deficient 
mice. Intestinal lipid secretion into lymph and appearance of 
TAGs in plasma were determined following intragastric gavage 
with FAs or olive oil.
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Results
Lipids accumulate in the proximal small intestine of CD36-deficient mice 
in vivo. [125I]15-(p-iodophenyl)-3-(R,S)-methyl pentadecanoic acid 
(BMIPP) and [125I]15-p-iodophenyl pentadecanoic acid (IPPA) are 
FA analogs used to study FA uptake in humans (20) and mice (5). 
Incorporation of these analogs into cellular lipids is similar to that 
of native long-chain FAs. BMIPP, which is 3-methylated, is slowly 
oxidized and retained longer in tissues, thus providing more sen-
sitivity, while the straight-chain IPPA is rapidly oxidized like native 
FA. We used these analogs to study the effects of CD36 deficiency 
on intestinal FA uptake and secretion in vivo following intragas-
tric gavage. BMIPP levels 2 hours after gavage were significantly 
increased in proximal segments of the small intestine of CD36-null 
mice but unaffected in the distal segments and colon (Figure 1A). 
These data suggested either increased FA uptake or reduced FA 
secretion by intestines of CD36-null mice.
As shown in Figure 1B, uptake of FAs was not altered in iso-
lated CD36-null enterocytes. Fecal TAG levels were comparable 
in WT and CD36-null mice fed a high-fat diet (3.15 ± 0.51 vs. 
2.76 ± 0.62 μg/mg of feces; n = 7; P = 0.31). In addition, these 
data indicated no global defect in fat absorption in CD36-
deficient mice, consistent with the study by Goudriaan et al. 
(21) and with the report that other proteins such as FA trans-
fer protein–4 (FATP4) may facilitate FA uptake by enterocytes 
(22). Thus, we hypothesized that intestinal lipid output may 
be impaired, leading to accumulation of the FA analog. To test 
this, we administered IPPA by gavage, and radioactivity in the 
gastrointestinal segments was measured at an extended time 
point (72 hours after gavage) to identify alterations in lipid out-
put as opposed to uptake. As shown in Figure 1C, IPPA levels 
were elevated in the proximal small intestine following the pat-
tern observed with BMIPP.
To determine whether the apparent defect in intestinal lipid out-
put affected intracellular TAG levels under conditions of high-fat 
loading, we examined intestinal sections obtained from mice fed 
a high-fat diet for 6 weeks using light microscopy. Sections from 
CD36-null mice showed abundant oil red O staining, while WT 
controls did not (Figure 2). In the CD36-deficient sections, stain-
ing was concentrated within the enterocytes of the upper villi and 
absent from the submucosa or serous coat.
CD36 is required for efficient intestinal lipid secretion. To examine lipid 
secretion directly, we equipped mice with duodenal and intestinal 
lymph duct fistulae (23). A lipid emulsion of [3H]TAGs was then 
infused via the duodenal fistula, and we determined secretion of 
TAGs into the mesenteric lymph by monitoring glycerol mass in 
the lymph fistula. As shown in Figure 3A, lymph TAG recovery in 
CD36-null mice reached 23% of the infusate at 6 hours compared 
with 67% in WT mice. 3H recovery in the lymph mirrored the TAG 
mass (at 6 hours: WT, 56.0% ± 14.0%; CD36-null, 23.5% ± 4.5%; 
P = 0.006). Together, these data indicated that lipid secretion from 
the intestine is significantly impaired in CD36-null mice.
We next examined whether the defect in TAG secretion in CD36-
deficient intestines reflected impaired FA delivery to the endoplas-
Figure 1
Accumulation of FA analogs in the small intestine after gavage with olive oil. (A) BMIPP levels 2 hours after gavage. WT (black bars) and CD36-
null (white bars) mice (n = 3) were administered BMIPP by gavage with olive oil. After 2 hours, intestinal segments (SI) were harvested from the 
mice and flushed with PBS. Levels of the FA analogs were determined by γ-ray spectroscopy. *P < 0.005. (B) FA uptake in primary enterocytes. 
Enterocytes were isolated from WT (filled squares) and CD36-null mice (open triangles). FA uptake at the indicated times was determined as 
described in Methods. (C) IPPA levels 72 hours after gavage. WT (black bars) and CD36-null (white bars) mice (n = 3) were administered IPPA 
by gavage with olive oil. After 72 hours, intestinal segments were harvested from the mice and flushed with PBS. Levels of the FA analogs were 
determined by γ-ray spectroscopy. **P < 0.0001.
Figure 2
Accumulation of neutral lipid in intestine from mice fed a high-fat diet. 
WT and CD36-null mice were fed a high-fat diet ad libitum for 6 weeks. 
Intestinal segments were fixed in paraformaldehyde/sucrose and pre-
pared for histology using standard techniques. Frozen sections were 
prepared, stained with oil red O and hematoxylin, and visualized by 
light microscopy at the indicated magnifications. L, intestinal lumen; M, 
mucosa; SC, serous coat; SM, submucosa.
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mic reticulum (ER), which contains the TAG synthetic enzymes and 
chylomicron assembly machinery. Primary enterocytes obtained 
from either WT or CD36-null mice were pulsed with micellar 
[3H]oleic acid. Microsomal fractions were then prepared, and incor-
poration of the label into the major lipid classes was determined. 
As shown in Figure 3B, recovery of 3H into microsomal TAGs was 
reduced by 47% in CD36-null enterocytes, which indicated a defect 
in microsomal TAG synthesis from exogenous FAs. Incorpora-
tion into diacylglycerol (DAG) also trended lower in CD36-null 
enterocytes (P = 0.07), and the DAG/TAG ratio was unaltered and 
similar to that observed in WT cells (data not shown). The lack of 
change in this ratio argued against impairment being at the level 
of DAG conversion to TAG by the enzyme diacylglycerol O-acyl-
transferase (Dgat). In line with this, abundance of mRNA for Dgat1 
and Dgat2, measured by quantitative PCR, was not altered by CD36 
deficiency (data not shown). In contrast to incorporation into TAG, 
3H into cholesteryl esters trended higher in CD36-null enterocytes, 
and a significant increase was measured for phospholipids. FA/TAG 
trafficking was also evaluated by electron microscopy of the 
proximal intestine after duodenal infusion of triolein. Large and 
centrally located lipid vacuoles were observed in CD36-deficient 
enterocytes, while WT cells exhibited mostly small and peripheral 
droplets (Figure 3C, arrows). These data were 
consistent with abnormal intracellular target-
ing of the FAs in CD36-deficient enterocytes.
Clearance of TAG-rich lipoproteins is defective in 
CD36-deficient mice. Since the fistula studies 
indicated reduced intestinal lipid secretion 
in CD36-null mice, the net effect of an olive 
oil gavage on the postprandial rise in plasma 
TAG concentration was examined. In WT 
mice, the level of plasma TAGs (determined by 
measuring plasma glycerol) was only modestly 
increased after an olive oil gavage (Figure 4A). 
In contrast, CD36-null mice displayed signifi-
cantly higher plasma TAG levels, which per-
sisted for more than 4 hours. These findings 
were surprising and inconsistent with a reduc-
tion of intestinal lipid secretion. To clarify this 
issue, we tested whether a decrease in chylomi-
cron clearance might be masking the reduced 
intestinal lipid output from CD36-null mice. 
Thirty minutes prior to an intragastric olive oil 
gavage, mice were administered saline or Triton 
WR-1339 (triton) by i.p. injection. Three hours 
after the gavage, the level of plasma TAGs was 
dramatically increased in WT mice given tri-
ton (Figure 4B), which indicated that plasma 
lipase activity and thus chylomicron clearance 
were blocked. In contrast, plasma TAG levels 
in CD36-null mice were similar whether or not 
triton was administered and were comparable 
to those of WT mice that received triton. Also, 
changes in hepatic VLDL secretion during the 
course of the experiment could not explain the 
differences in plasma TAG levels. Plasma TAG 
levels in triton-treated fasted mice were com-
parable in both genotypes (Figure 4C). These 
data strongly suggested that CD36 deficiency 
interferes with lipase activity in vivo.
Chylomicrons are secreted from the intestine as large particles, 
which become smaller through the lipolytic actions of lipoprotein 
lipase (LPL); thus, chylomicron size can provide a measure of lipase 
activity in vivo. Chylomicrons were isolated from the plasma of 
mice 3 hours after an olive oil gavage, and their size was measured 
by negative-staining electron microscopy. Chylomicrons from WT 
mice were primarily (97%) less than 101 nm in diameter (Figure 4D), 
while the majority of chylomicrons from CD36-null mice (78%) were 
201–700 nm in diameter, which further indicated a lipase defect.
We also examined the plasma levels of the major apolipoproteins 
involved in chylomicron assembly and clearance. ApoB is the main 
protein component of chylomicrons, and elevated plasma TAG 
levels are typically associated with elevated plasma apoB levels. As 
expected, apoB concentrations tended to be higher in the plasma of 
olive oil–fed CD36-null mice compared with WT mice (118.2 ± 34.8 
vs. 68.0 ± 5.7 mg/l; n = 5; P = 0.09), even though fasting apoB lev-
els were not increased in CD36-null mice (data not shown). ApoE 
binds TAG-rich lipoproteins and is required for the clearance of 
chylomicron remnants by the liver. To measure both the levels of 
apoE and its association with postprandial lipids, we isolated the 
VLDL/chylomicron fractions from the plasma by size-exclusion 
chromatography. As shown in Figure 5, relative apoE levels in these 
Figure 3
Lipid trafficking in the intestine. (A) Duodenal and intestinal lymph duct fistulae were sur-
gically implanted in anesthetized WT (filled squares) and CD36-null (open squares) mice 
(n = 4–6). Following duodenal infusion of the lipid emulsion, lymph was collected from the 
lymph duct fistula. The amount of TAG mass recovered per hour in the lymph (expressed 
as a percentage of the infusate) was determined by scintillation spectroscopy. *P < 0.05; 
***P < 0.001. (B) Primary enterocytes from anesthetized WT (black bars) and CD36-null 
(white bars) mice were prepared and pulsed with a lipid mixture containing [3H]oleic acid. 
The relative incorporation of 3H into microsomal lipids was determined. The combined data 
from 2 experiments (n = 4 plates per experiment) is shown. CE, cholesteryl ester; DAG, dia-
cylglycerol; PL, phospholipid. #P = 0.03; †P < 0.00001. (C) Fixed segments of the proximal 
intestine were stained with uranyl acetate and embedded using standard methods. Ultrathin 
sections were prepared, stained with Reynolds’ lead citrate, and examined under a Hitachi 
H-600 electron microscope. Red arrows indicate the positions of lipid droplets.
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fractions were higher in CD36-null mice independent of the dietary 
status, and the highest apoE levels covaried with plasma TAG levels. 
An oral fat load elevated the apoE level in these fractions in both 
WT and CD36-null mice.
CD36-deficient mice have normal postheparin lipase activity. Posthepa-
rin LPL and hepatic lipase (HL) activity in plasma did not differ 
between WT and CD36-null mice (Figure 6A). Cell-associated lipase 
activity was also measured in heart tissue collected in the absence 
of heparin, and no decrease in LPL activity was observed (data not 
shown). LPL activity can be inhibited by plasma FAs (24). CD36-
null mice have elevated fasting plasma FA levels (6, 25), but it is 
not known whether FA levels also rise postprandially and interfere 
with LPL activity and lipoprotein clearance. As shown in Figure 6B, 
plasma FA levels measured after olive oil gavage were significantly 
higher in CD36-null mice and were tightly correlated with plasma 
TAG levels (Figure 6C) (r = 0.7452; P = 0.0001; n = 19).
Apoc3 mRNA abundance is altered in CD36-null mice. LPL activity 
can be modulated by apolipoproteins, particularly apoC-I, apoC-II, 
and apoC-III. The abundance of the mRNAs — Apoc1, Apoc2, and 
Apoc3, respectively — encoding these proteins was measured in the 
proximal intestine (Apoc2/Apoc3) and liver (Apoc1/Apoc2/Apoc3). 
No significant differences in the abundance of the Apoc1 or Apoc2 
mRNAs were detected between WT and CD36-null mice following 
olive oil gavage (Figure 7). On the other hand, the mRNA encod-
ing apoC-III, a potent LPL inhibitor, was significantly increased 
in CD36-null mice in both intestine and liver. Apoc3 mRNA lev-
els in the intestine correlated with plasma TAG levels (r = 0.4141; 
P = 0.039, n = 19), and a similar trend was detected in the liver 
(r = 0.3720; P = 0.059; n = 19).
Discussion
The role of CD36 in FA uptake in muscle and adipose tissue has 
been well documented both in vitro and in vivo. The current 
study illustrates for the first time to our knowledge that CD36 is 
important for optimal utilization of dietary FAs and triglycerides. 
In CD36-null mice, secretion of lipid into the mesenteric lymph 
is significantly reduced, but this effect is masked in vivo, as CD36 
also appears to regulate the catabolism of TAG-rich chylomi-
crons from the plasma.
Enterocyte CD36 may target the FAs to the TAG secretion pool. The 
reduced TAG output into intestinal lymph in CD36-null mice 
appeared to reflect mis-targeting of the FAs. Fat feeding or oral 
administration of FA analogs resulted in accumulation of neu-
tral lipid in CD36-deficient enterocytes. However, these cells 
also exhibited reduced incorporation of exogenous FAs into 
microsomal TAGs. Enteric neutral lipid has been proposed to 
exist in at least 2 pools: a cytosolic storage pool and a microsomal 
secretion–coupled pool (reviewed in ref. 26). It is thought that 
de novo synthesis in the ER lumen is the major source of chy-
lomicron TAGs. The data strongly suggest that CD36 deficien-
cy results in impaired FA targeting to the ER for chylomicron 
Figure 4
Plasma TAG metabolism in vivo. (A) Postprandial plasma TAGs. WT 
(filled squares) and CD36-null (open squares) mice (n = 4) received 
an intragastric gavage of olive oil (16.5 μl/g). Plasma was collected 
at the indicated time points and TAG levels measured. *P < 0.05; 
**P < 0.001. (B) Effect of triton on postprandial plasma TAGs. WT 
(black bars) and CD36-null (white bars) mice (n = 3) received i.p. injec-
tions of saline or triton 30 minutes before an intragastric gavage of 
olive oil (16.5 μl/g) was administered. Plasma was collected 3 hours 
after injection and TAG levels measured. #P < 0.0001. (C) Effect of tri-
ton on fasting plasma TAGs. WT (filled squares) and CD36-null (open 
squares) mice (n = 4) received i.p. injections of triton. Plasma was 
collected at the indicated time points and TAG levels measured. (D) 
Chylomicron size after an oral fat load. Chylomicrons were isolated 
from the plasma of WT (black bars) and CD36-null (white bars) mice 3 
hours after an intragastric gavage of olive oil (16.5 μl/g). Particle size 
was determined by negative-staining electron microscopy.
Figure 5
TAG-associated apoE from plasma. WT (filled squares) and CD36-null 
(open circles) mice (n = 3) received an intragastric gavage of saline or 
olive oil (16.5 μl/g). After 2 hours, plasma was collected and pooled and 
the VLDL/chylomicron fraction isolated by size-exclusion chromatogra-
phy. Plasma TAG and apoE levels were measured in each fraction.
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assembly. The mechanism by which CD36 would target dietary 
long-chain FAs to the secretion-coupled pool in the ER is com-
pletely unknown but may involve intracellular trafficking of the 
protein, which has been shown to cycle between the cell surface 
and intracellular membranes (27). A working hypothesis is that 
following an oral fat load, CD36-rich membrane vesicles help 
shuttle FAs to ER enzymes required for TAG synthesis (Figure 8). 
For example Dgat1 (28) has been postulated to localize on the 
luminal side of the ER (29), and FA delivery to Dgat1 and other 
esterification enzymes could become limiting.
Defect in tissue FA clearance inhibits lipolysis of blood TAGs. Several 
lines of evidence indicate that CD36 deficiency results in defec-
tive lipoprotein lipolysis by LPL. Under fasting conditions, the 
level of VLDL-associated TAGs is elevated in mice that lack CD36, 
while LDL-associated TAGs are practically absent (6). Olive oil 
gavage greatly increased plasma TAG levels in CD36-null mice as 
compared with WT mice. Triton, a potent inhibitor of LPL and 
HL, caused a 6-fold increase in the level of plasma TAGs in WT 
mice following olive oil gavage but had no significant effect in 
CD36-null mice. In addition, WT and CD36-null mice had similar 
plasma TAG levels following triton administration in the absence 
of an olive oil gavage, which indicates that hepatic TAG secretion 
was not a contributing factor. Also, in the absence of triton, chy-
lomicrons remained large in CD36-null mice, unlike particles in 
WT mice. All the above data support the interpretation that CD36 
deficiency impairs chylomicron catabolism. Analysis of plasma 
apolipoprotein levels indicated that chylomicrons from WT and 
CD36-null mice had appropriate levels of apoB and apoE. It is 
thus unlikely that the decreased catabolism was due to the par-
ticles having abnormal structural components.
Plasma LPL and HL and cell-associated lipase activity were not 
reduced in CD36-deficient mice, which implied that local factors 
were modulating lipase activity in vivo. FAs can displace LPL from 
the cell surface, thereby reducing its activity (24, 30, 31). Converse-
ly, promotion of tissue FA esterification and trapping with acyla-
tion-stimulating protein enhances adipocyte LPL activity (32). 
CD36 is required for efficient tissue FA uptake (5), so inhibition 
of LPL activity in CD36-deficient mice likely results from the lack 
of peripheral FA removal. In line with this, a tight correlation was 
observed between plasma TAG and FA levels in WT and CD36-null 
mice following an oral fat load.
Additional factors may contribute to or account for the reduced 
plasma TAG hydrolysis in vivo. Induction of Apoc3 gene expression 
in the liver and intestine may increase plasma apoC-III levels and 
thus inhibit LPL activity. In addition, CD36 is a receptor for many 
lipoprotein classes in vitro (33) and may serve as a docking site for 
lipoproteins on the cell surface (as suggested in ref. 12), which can 
then be lipolyzed by cell-associated LPL.
The data presented herein suggest that CD36 regulates 
intestinal lipid secretion and peripheral clearance of intestine-
derived lipoproteins (Figure 8), thus linking dietary fat intake 
and utilization. A high-fat diet increases Cd36 mRNA abun-
dance in the intestine as well as in the heart and adipose tissue 
(19, 34, 35). This coordinate regulation favors intestinal TAG 
synthesis/chylomicron secretion and peripheral chylomicron 
hydrolysis via increased FA clearance and elevated LPL activ-
ity. It may also promote FA oxidation by muscle (36) and TAG 
storage by adipose tissue (35), processes that appear to be rate 
limited by FA uptake and CD36 levels.
Postprandial lipemia in human CD36 deficiency. CD36-deficient 
humans exhibit abnormalities of plasma lipid profiles including 
higher postprandial TAG levels (12, 14, 16). Based on the data 
presented here, human dyslipidemia during CD36 deficiency may 
result from defects in the clearance of both FAs and TAGs in both 
the fed and fasted conditions. Defective clearance of dietary TAGs 
has not been documented in CD36-deficient humans but would 
be implied by the observed increase of plasma apoB-48 levels (16). 
Figure 6
Postheparin lipase activity and plasma FA levels. (A) 
LPL and HL activity. WT (black bars) and CD36-null 
(white bars) mice (n = 5) received i.p. injections of 
heparin. After 30 minutes, plasma was collected and 
lipase activity measured. (B and C) Plasma FA levels 
correlate with plasma TAG levels. Fasted WT (black 
bars) and CD36-null (white bars) mice (n = 4–6) 
received olive oil (3.5 μl/g) by gavage. Plasma was 
harvested 2–3 hours after gavage. Plasma FA levels 
were measured (B) and correlated with plasma TAG 
levels (C). *P < 0.001; **P < 0.02.
Figure 7
Intestinal and hepatic Apoc mRNA levels. Fasted WT (black bars) and 
CD36-null (white bars) mice (n = 4–6) received olive oil (3.5 μl/g) by 
gavage. Intestinal and hepatic tissues were harvested 2–3 hours after 
gavage and used to prepare total RNA. Hepatic and intestinal Apoc1, 
Apoc2, and Apoc3 mRNA abundance was measured by quantitative 
RT-PCR and related to that of cyclophilin. For each gene, the abundance 
in saline-treated WT mice was taken as 1 (dashed line). *P < 0.001.
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Since apoB-48 in humans is only produced in the intestine, a high 
level of plasma apoB-48 is consistent with impaired chylomicron 
clearance and TAG hydrolysis. Hypertriglyceridemia has been 
linked to the etiology of type 2 diabetes and atherosclerosis (37), 
and it is important to examine whether CD36 deficiency alters sus-
ceptibility to these pathologies, particularly when they result from 
high-fat diets. In this context, Ma et al. (15) reported that a com-
mon haplotype at the CD36 locus was associated with an increased 
risk of cardiovascular disease in type 2 diabetes.
Diabetic subjects exhibit extended postprandial lipemia, and as 
our data suggest, a potential mechanism for this abnormality is 
the high level of plasma FA that is common in diabetes (38). Our 
findings further emphasize the importance of treatments aimed 
at improving tissue FA clearance in patients with diabetes. Thus, 
enhancing tissue FA uptake by upregulation of CD36 may mediate 
a significant component of the beneficial effects of thiazolidin-
ediones on blood lipids and energy utilization (38–40).
Methods
Animals. CD36-null mice backcrossed to the C57BL6/J background (5) 
and WT (C57BL6/J) mice (8–12 weeks of age) were maintained on stan-
dard rodent chow (unless otherwise indicated) under a normal light-dark 
cycle. All experimental procedures were approved by the Institutional 
Animal Care and Use Committee of the Division of Laboratory Animal 
Resources at the State University of New York at Stony Brook. Primary 
enterocytes were prepared from intestinal segments of starved mice as 
described in ref. 41.
Intestinal lipid analysis. For in vivo studies, mixtures of FA analogs were pre-
pared as follows: 40 μCi of either BMIPP or IPPA (Oak Ridge National Labo-
ratory) was evaporated under N2(g) in a glass vial and resuspended in 2 ml 
warm olive oil by gentle sonication. Triton (500 mg/kg) was administered 
to fasted (8–12 hours) mice by i.p. injection, and 30 minutes later, the FA 
analog/olive oil mixture (6 μl/g) was administered by intragastric gavage. 
Mice were sacrificed 2 or 72 hours after gavage as indicated in Figure 1, and 
4 intestinal segments of equal length plus the colon were collected, saline-
washed, and associated radioactivity measured using γ-ray spectroscopy.
For in vitro studies in primary enterocytes, [14C]palmitate:BSA com-
plexes were prepared in a solution of 160 μM sodium palmitate (Sigma-
Aldrich), 5 mM glucose, and 40 μM FA-free albumin (Fraction V; Sigma-
Aldrich) in Krebs-Ringer HEPES (KRH) buffer (pH 7.4). While stirring, 
we added 0.5 μCi/ml of [1-14C]palmitic acid (55 mCi/mmol; ICN Bio-
medicals Inc.) and unlabeled palmitic acid to produce a 1:1 solution. 
Primary enterocytes (25 μl) resuspended in KRH were added to a 25-μl 
aliquot of [14C]palmitate:BSA complex for the indicated times. The uptake 
reaction was stopped by the addition of ice-cold stop solution (200 μl; 
300 μM phloretin [Sigma-Aldrich] in KRH) and immediately overlaid on 
an ice-cold plug of Ficoll-Paque (Amersham Biosciences; diluted 6-fold in 
PBS) in 6 × 44 mm microcentrifuge tubes. Cells were separated from free 
[14C]palmitate by centrifugation at 12,000 g for 1 minute. The cell pellet 
was cut from the bottom of the tube, incubated overnight in scintillation 
fluid, and quantitated by scintillation spectroscopy. Background uptake 
and/or nonspecific cell association of the [14C]palmitate were routinely 
subtracted from results and were determined by adding the enterocytes 
to ice-cold mixtures of [14C]palmitate:BSA and stop solution. The sam-
ples were then processed as described above. No difference in background 
uptake was observed between enterocytes isolated from WT and CD36-null 
mice (data not shown).
To measure FA partitioning, primary enterocytes were plated and pulsed 
with a labeling mixture (DMEM containing 0.4 mM sodium taurocho-
late, 0.52 mM sodium taurodeoxycholate, 0.29 mM phosphatidylcholine, 
0.45 mM oleic acid, 0.16 mM 1-oleoyl-rac-glycerol, 0.05 mM cholesterol) 
containing 3.3 μCi/ml [9,10-H(N)]oleic acid for 1 hour at 37°C/5% CO2. 
Cells were washed by centrifugation in cold PBS and microsomes were 
prepared as described in ref. 42. Lipids were extracted using the method 
of Folch et al. (43), resuspended in chloroform, and separated by TLC in 
hexane/isopropyl ether/glacial acetic acid 60:40:4 (vol/vol/vol). After the 
different lipid species were identified according to standards, bands cor-
responding to the lipids indicated in Figure 1 were scraped, incubated over-
night in Scintilene scintillation fluid (Fisher Scientific International Inc.), 
and quantified by scintillation spectroscopy. The distribution of 3H in the 
different lipid classes is expressed as a percentage of total cellular counts, 
with levels in WT cells taken as 100%.
Levels of fecal TAG were determined from mice fed a high-fat, high-
carbohydrate diet (F3282; Bioserve) ad libitum. TAGs were extracted 
as described above and quantitated using the Triglycerides Reagent 
(Thermo Electron Corp.) and standard curves generated with Glycerol 
Standard (Sigma-Aldrich).
Lipid secretion into mesenteric lymph. Live animals equipped with duo-
denal and intestinal lymph duct fistulae (23) were infused with a lipid 
emulsion containing 13.3 mM [3H]triolein, 2.6 mM cholesterol, 2.9 mM 
egg phosphatidylcholine, and 19.0 mM sodium taurocholate in PBS 
(pH 6.4) at a rate of 0.3 ml/h. Lymph was collected hourly for 6 hours 
and the recovery of 3H or TAGs (expressed as a percentage of the infusate) 
determined by scintillation spectroscopy or using Triglycerides Reagent 
as described above, respectively.
Plasma lipid and lipoprotein analysis. Whole blood was collected from the 
tail vein into EDTA-treated tubes, and the plasma was isolated by low-
speed centrifugation. TAG levels were measured using the Triglycerides 
Reagent as described above.
We quantified apoB in plasma using an automated immunoturbidi-
metric assay (44). For quantification of apoE, the plasma was first frac-
tionated using size exclusion chromatography as described in ref. 45. We 
subjected the VLDL/chylomicron fractions to SDS–PAGE on 10% gels, and 
after transferring them to nitrocellulose, used α-apoE and the ECL kit for 
immunodetection (Amersham Biosciences).
Lipase activity. Lipase activity in postheparin plasma and in homogenized 
hearts was analyzed as previously described (46, 47).
Histology. Intestines were obtained from mice fed a high-fat, high-carbo-
hydrate diet (F3282; Bioserve) ad libitum for 6 weeks. They were divided 
into 3 segments of equal length, and the proximal segment was gently 
flushed with PBS and fixed by 2 overnight incubations at 4°C, first in 4% 
paraformaldehyde and then in 30% sucrose. Intestinal rings (0.5 cm) were 
Figure 8
CD36 and dietary FA utilization. In the presence of CD36, FAs are tar-
geted to a secretion-coupled pool within the ER and efficiently packaged 
into TAG chylomicrons. In the plasma, LPL acts to liberate the FAs from 
chylomicron-associated TAGs. Clearance of released FAs by periph-
eral tissues via CD36 prevents feedback inhibition of LPL (33, 34). 
Coordinated upregulation of CD36 expression by dietary FAs (37) 
would enhance both FA absorption and peripheral utilization.
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cut from the fixed segments and frozen in cryoembedding media (OCT) 
for subsequent cryostat sectioning at 7–10 μm. Sections were applied to 
gelatin-coated glass slides, stained with oil red O and hematoxylin, and 
mounted with glycerol/water (50:50) media.
Electron microscopy. To measure lipoprotein size, we layered pooled 
aliquots of sera (200 μl) under 600 μl 0.15 M NaCl and subjected them to 
centrifugation at 117,320 g for 30 minutes in a tabletop ultracentrifuge. 
We removed chylomicrons, subjected them to negative-staining electron 
microscopy using aqueous uranyl acetate, and viewed them under a Zeiss 
902 electron microscope.
To asses FA trafficking, we administered an emulsion of triolein to 
WT and Cd36-null mice via a duodenal fistula as described above. Proxi-
mal intestinal sections were then prepared and visualized essentially as 
described in ref. 48. Briefly, intestinal tissue was fixed for 2 hours in 2% glu-
taraldehyde and for an additional 2 hours in 0.1 M cacodylate buffer. The 
tissue was then postfixed in 1% osmium tetroxide and stained en bloc in 
uranyl acetate. Following dehydration, samples were infiltrated in acetone/
Spurr’s mixture and embedded in Spurr’s resin. Ultrathin sections were cut 
on a Reichert Ultracut ultramicrotome, stained with Reynolds’ lead citrate, 
and examined under a Hitachi H-600 electron microscope.
Apolipoprotein mRNA abundance. Fasted (8–12 hours) mice were adminis-
tered an intragastric gavage of saline or olive oil, and tissues were harvested 
2.5 hours later. Total RNA isolation, reverse transcription, and real-time 
quantitative PCR were performed as previously described (45). Gene-specific, 
intron-spanning oligonucleotides and SYBR Green I (Sigma-Aldrich) were 
used to detect amplicon production in a GeneAmp PCR System 9700 (Applied 
Biosystems). Cyclophilin was used as internal control. For each gene, mRNA 
abundance in saline-treated WT mice was taken as 1. The primer sequences 
were: cyclophilin, 5′-TCCAAAGACAGCAGAAAACTTTCG, 5′-TCTTCTT-
GCTGGTCTTGCCATTCC; Apoc1, 5′-TGTCCTGATTGTGGTCGTAGCC, 
5′-CAAATAGCCTCTAGAGAACCAGGC; Apoc2, 5′- TCCTGGTCATCCT-
GATGTTGGG, 5′- TGCCTAGCGTAAGTGCTCATGGC; Apoc3, 5′-CTACTC-
CAGGTACGTAGGTGCC, 5′-TGGTCCTCAGGGTTAGAATCCC.
Statistical analysis. The data shown are mean ± SEM. Differences between 
treatment groups were evaluated using Student’s t test or ANOVA 
(Bartlett’s test for equal variances and the Bonferroni multiple comparison 
test. Correlation coefficients (r) were determined using the Pearson prod-
uct-moment method. P < 0.05 was considered statistically significant.
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